Quick Takeaways
- T. Rowe Price Investment Management, Inc. filed SCHEDULE 13G/A for ASCENDIS PHARMA A/S - ADR ADR (ASND).
- Disclosed ownership: 4.8%.
- Date of event: 30 Sep 2025.
T. Rowe Price Investment Management, Inc. - 30 Sep 2025 SCHEDULE 13G/A Report for ASCENDIS PHARMA A/S - ADR ADR (ASND)
- Filing Manager
- T. Rowe Price Investment Management, Inc.
- Reporting Manager
- T. Rowe Price Investment Management, Inc.
- Security
- ASCENDIS PHARMA A/S - ADR ADR
- Symbol
- ASND
- Shares outstanding
- 55,574,229 shares
- Disclosed Ownership
- 2,667,563 shares
- Ownership
- 4.8%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Nov 2025, 12:18:24 UTC
- Date of event
- 30 Sep 2025
- Previous filing
- 14 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"T. Rowe Price Investment Management, Inc. disclosed 4.8% ownership in ASCENDIS PHARMA A/S - ADR ADR (ASND) on 30 Sep 2025."
What Changed
- Previous schedule filing date: 14 Aug 2025.
- Current filing was accepted on 14 Nov 2025, 12:18.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 4.8% | 2,667,563 | 2,661,602 | 0 | Ellen York | Vice President |